




22W1615

|   |                                     |                                  |  |                                   |                                 |
|---|-------------------------------------|----------------------------------|--|-----------------------------------|---------------------------------|
| <b>AMENDMENT TRANSMITTAL LETTER (Small Entity)</b>  |                                     |                                  |  | Docket No.<br><b>P24375-A USA</b> |                                 |
| Applicant(s): <b>Kenneth Iain Cumming and Zebunnissa Ramtoola</b>   |                                     |                                  |  |                                   |                                 |
| Application No.<br><b>09/510,560</b>  | Filing Date<br><b>02/22/2000</b>    | Examiner<br><b>Bennett Celsa</b> | Customer No.<br><b>23307</b>   | Group Art Unit<br><b>1615</b>     | Confirmation No.<br><b>3011</b> |
| <div style="position: relative;"><div style="position: absolute; top: 0; left: 0; width: 100px; height: 100px; border: 2px solid black; border-radius: 50%; text-align: center; line-height: 100px; font-size: 10px;">COPY<br/>FEE<br/>AUG 08 2005<br/>PATENT &amp; TRADEMARK OFFICE</div><div style="position: absolute; top: 10px; left: 10px;">Invention:</div><div style="position: absolute; top: 15px; left: 15px;"><b>SOLID ORAL DOSAGE FORM CONTAINING AN ENHANCER</b></div></div>  |                                     |                                  |  |                                   |                                 |
| <u>COMMISSIONER FOR PATENTS:</u>  |                                     |                                  |  |                                   |                                 |
| Transmitted herewith is an amendment in the above-identified application.   |                                     |                                  |  |                                   |                                 |
| <input checked="" type="checkbox"/> Applicant claims small entity status. See 37 CFR 1.27   |                                     |                                  |  |                                   |                                 |
| The fee has been calculated and is transmitted as shown below.  |                                     |                                  |  |                                   |                                 |
| <b>CLAIMS AS AMENDED</b>  |                                     |                                  |  |                                   |                                 |
|   | CLAIMS REMAINING<br>AFTER AMENDMENT | HIGHEST #<br>PREV. PAID FOR      | NUMBER EXTRA<br>CLAIMS PRESENT   | RATE                              | ADDITIONAL<br>FEE               |
| TOTAL CLAIMS  | 74 -                                | 79 =                             | 0  | x \$25.00                         | \$0.00                          |
| INDEP. CLAIMS   | 13 -                                | 9 =                              | 4  | x \$100.00                        | \$400.00                        |
| Multiple Dependent Claims (check if applicable) <input type="checkbox"/>  |                                     |                                  |  |                                   | \$0.00                          |
| <b>TOTAL ADDITIONAL FEE FOR THIS AMENDMENT</b>  |                                     |                                  |  |                                   | <b>\$400.00</b>                 |
| <div><input type="checkbox"/> No additional fee is required for amendment.</div> <div><input type="checkbox"/> Please charge Deposit Account No. _____ in the amount of _____</div> <div><input type="checkbox"/> A check in the amount of _____ to cover the filing fee is enclosed.</div> <div><input checked="" type="checkbox"/> The Director is hereby authorized to charge payment of the following fees associated with this communication or credit any overpayment to Deposit Account No. <b>19-5425</b><div style="margin-left: 20px;"><input checked="" type="checkbox"/> Any additional filing fees required under 37 C.F.R. 1.16.<br/><input type="checkbox"/> Any patent application processing fees under 37 CFR 1.17.</div></div> <div><input checked="" type="checkbox"/> Payment by credit card. Form PTO-2038 is attached.</div> |                                     |                                  |  |                                   |                                 |
| <b>WARNING: Information on this form may become public. Credit card information should not be included on this form. Provide credit card information and authorization on PTO-2038.</b>   |                                     |                                  |  |                                   |                                 |
| <div style="text-align: center;"><br/>_____<br/><i>Signature</i></div> <div style="border: 1px solid black; padding: 5px; margin-top: 5px;"><b>Marilou E. Watson</b><br/><b>Synnestvedt &amp; Lechner LLP</b><br/><b>2600 Aramark Tower</b><br/><b>1101 Market Street</b><br/><b>Philadelphia, PA 19107-2950</b><br/><br/><b>Telephone: 215-923-4466</b><br/><b>Facsimile: 215-923-2189</b></div>   |                                     |                                  | <div>Dated: <b>August 5, 2005</b></div> <div style="border: 1px solid black; padding: 5px; margin-top: 10px;"><div style="font-size: 0.8em;">I certify that this correspondence is being deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to "Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450" [37 CFR 1.8(a)] on <u>August 5, 2005</u> (Date)</div><div style="text-align: center; margin-top: 10px;"><br/>_____<br/><i>Signature of Person Mailing Correspondence</i><br/><b>Rita C. Clancy</b><br/><i>Typed or Printed Name of Person Mailing Correspondence</i></div></div> |                                   |                                 |
| CC:   |                                     |                                  |  |                                   |                                 |



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re/ Application of Kenneth Iain Cumming and  
Zebunnissa Ramtoola  
Application No. 09/510,560  
Filed February 22, 2000  
Confirmation No. 3011


Examiner: Bennett Celsa  
Art Unit 1615

SOLID ORAL DOSAGE FORM CONTAINING AN ENHANCER

(Attorney Docket No. P24,375-A USA)

CERTIFICATE OF MAILING

I hereby certify that this correspondence is being deposited with the United States Postal Service as first-class mail, postage prepaid, in an envelope addressed to: Mail Stop AF, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450 on August 5, 2005.

  
Rita C. Clancy

REPLY UNDER 37 C.F.R. § 1.111  
TO THE OFFICE ACTION MAILED MAY 18, 2005

Mail Stop Amendment  
Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

Sir:

This Reply is responsive to the Office Action, mailed May 18, 2005, in the above-identified application. Reconsideration of the application is requested respectfully in view of the following amendments and remarks.

Amendments to the Claims are referenced in the Listing of Claims which begins on page 2 of this Reply. Remarks begin on page 17 of this Reply.